Funding profile · Longevity therapeutics

Dorian Therapeutics

Dorian took more money from two federal agencies than it ever disclosed from investors, filed no Form D under its own name, and sold to Altos Labs in May 2025 on undisclosed terms.

$4.51MFederal awards on record, NIA and NCI, 2021 to 2025
$4.18MNIA cooperative agreement for the osteoarthritis program, four fiscal years
$336KNCI award for the CAR-T senescence program
NoneForm D filings on EDGAR under the company’s own name

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2018 Y Combinator, Summer 2018 $150,000 reported Y Combinator Press report
2018 Accelerator Not disclosed StartX Company-stated
By May 2021 Venture backers named Not disclosed Longevity Capital, Y Combinator, Blumberg Capital, Pacific 8 Ventures Company release
By 2022 Individual backers named Not disclosed Laura Deming, Celestine Schnugg of Boom Capital, Yodfat Harel Buchris of Blumberg Capital Company-stated
Feb 2022 Gaingels Dorian LLC, a Vermont pooled vehicle $111,998 16 investors, managed by Gaingels Management LLC Link unconfirmed
Sep 2021 to May 2025 Federal awards $4,513,772 NIA U44 AG074108; NCI R43 CA265636 NIH
May 2025 Acquisition Not disclosed Altos Labs Press report

What the filings show

Gaingels Dorian LLC · Form D · filed Feb 16, 2022

First sale
Feb 8, 2022
Type
Limited liability company, Vermont, formed 2021
Offered
$111,998 equity
Sold
$111,998 · $0 remaining
Investors
16 · average about $7,000 · minimum accepted $1,500
Exemption
Rule 506(b)
Related persons
David Beatty, manager of Gaingels Management LLC, which manages the issuer
Filing
SEC EDGAR, CIK 0001910425
Caution
The filing names no portfolio company. Gaingels commonly names a vehicle after the company it invests in, but no public record ties this one to Dorian Therapeutics.

Reading the filings

  1. Dorian never filed a Form D.EDGAR holds no registrant named Dorian Therapeutics. A company can raise privately under Section 4(a)(2) instead of Regulation D and owe no Form D at all, so the absence does not mean no money moved. It does mean the equity story here rests entirely on what the company and the press chose to say.
  2. The taxpayer was the largest disclosed funder.$4,178,124 from the National Institute on Aging plus $335,648 from the National Cancer Institute is $4,513,772 of non-dilutive money, against a single reported equity figure of $150,000 at the Y Combinator stage and no disclosed amount for anything after it. For a company of eight people over seven years, the federal awards were very likely the bulk of the budget.
  3. A vehicle carries the name, and the tie is unproven.Gaingels Dorian LLC sold $111,998 to 16 investors in February 2022, about $7,000 each, against a $1,500 minimum. Those are angel syndicate economics, not fund economics. Gaingels usually names a vehicle for its target, but the filing itself names no company and nothing public confirms the connection. Treat it as a lead, not a fact.
  4. A separate Dorian Inc. is not this company.EDGAR carries a Form D from Dorian Inc., CIK 0001818452, a Delaware corporation in Walnut, California, classified as Other Technology, which sold $5,449,702 to 15 investors from June 2020. Its officers have no connection to Dorian Therapeutics. Any funding total that sweeps in this filing is wrong.
  5. The board outweighed the balance sheet.Two directors are documented only in other companies’ proxy statements: Jeff George, formerly chief executive of Sandoz and of Alcon, and Aya Jakobovits, founding chief executive of Kite Pharma. That is unusual governance for a preclinical company with eight employees and no Form D.
  6. The exit disclosed nothing.Neither Altos Labs nor Dorian published terms. Altos is private and files no reports, so a consideration figure is unlikely ever to surface. Fight Aging! read the deal as a possible acquihire in a poor funding market, which is commentary rather than disclosure.

Commercial signals

Signal Detail Source type
Regulatory No FDA marketing submission, as expected for a preclinical small molecule. No IND disclosed. Public record
Clinical No trial registered on ClinicalTrials.gov. Two SEC proxy statements describe the company as pre-clinical. Public record
Partnership HitGen, Shanghai listed, DNA encoded library screening from May 2021. Undisclosed upfront plus milestones payable by Dorian to HitGen. Company release
Partnership Rottapharm Biotech and the University of Milano Bicocca appear as co-authors on the 2023 and 2024 osteoarthritis abstracts. Public record
Intellectual property WO2021042073A1, priority Aug 29, 2019, entered Europe, Australia, Canada and China. Google Patents lists it as Ceased and notes that the status is an assumption. Public record
Exit Acquired by Altos Labs, reported May 21, 2025. The company domain now serves the Altos Labs website. Independent

What to watch

  • Any Altos Labs disclosure of a senescence program or a DT-201 successor. Altos is private and under no obligation to make one.
  • Renewal or abandonment of the USP16 patent family in each national office.
  • A closeout publication from the NIA cooperative agreement, which ran to May 2025.
  • Whether Gaingels lists Dorian Therapeutics in any portfolio disclosure, which would settle the February 2022 vehicle.

The Dorian Therapeutics story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Alixia: Shared investor: Gaingels. A San Francisco drug discovery company that treats a tumor as an ecosystem rather than as a single mutation
  • Humane Genomics: Shared investor: Gaingels. A New York biotech engineering synthetic RNA viruses that are designed to infect and kill only cancer cells
  • Ochre Bio: Shared investor: Gaingels. An Oxford company that designs RNA drugs and tests them in whole human donor livers kept alive on machines
  • Parallel Bio: Shared investor: Gaingels. Miniature human lymph nodes, grown from donated tissue and run side by side across hundreds of donors, used to test drugs and vaccines before anyone takes them

Sources

  1. Public recordNIH RePORTER, NIA award U44 AG074108 and NCI award R43 CA265636NIH · FY2021 to FY2024
  2. Public recordForm D, Gaingels Dorian LLC, CIK 0001910425SEC · Feb 16, 2022
  3. Public recordForm D, Dorian Inc., CIK 0001818452, a separate companySEC · Sep 16, 2020
  4. Public recordEDGAR company and full text search for Dorian TherapeuticsSEC · accessed Sep 22, 2026
  5. Public record908 Devices and Adicet Bio proxy statements, Dorian director biographiesSEC EDGAR · 2021 and 2022
  6. Public recordPatent application WO2021042073A1, Methods and compositions for modulating cellular agingWIPO, via Google Patents · priority Aug 29, 2019
  7. Public recordDorian Therapeutics Inc, SBIR company profile, CAGE 8QX05inKnowVation · Feb 17, 2024
  8. IndependentAltos Labs acquires Dorian Therapeutics, with founding and investor historyBeBeez International, Salvatore Bruno · May 26, 2025
  9. IndependentJeff Bezos-backed, lifespan-focused Altos Labs buys small biotech with Stanford rootsSan Francisco Business Times, Ron Leuty · May 21, 2025
  10. IndependentAltos Labs snaps up Dorian TherapeuticsLongevity.Technology, Danny Sullivan · May 23, 2025
  11. IndependentAltos Labs broadens scope to senotherapeutics via acquisitionFight Aging!, Reason · May 30, 2025
  12. CompanyDorian and HitGen announce research collaborationHitGen and Business Wire · May 24, 2021
  13. CompanyDorian Therapeutics founder profile and investor listMBC BioLabs · accessed Sep 22, 2026
  14. CompanyDorian Therapeutics company page, batch, team size and acquired statusY Combinator directory · accessed Sep 22, 2026

Compiled from SEC, NIH and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Dorian Therapeutics. This page is not an offer to sell or a recommendation to buy any security.